Feature

What does a pig-to-human heart transplant mean for medicine?


 

‘This field needs to evolve’

Dr. Mehra also flagged the procedure’s potential cost should it become mainstream. Perhaps that would promote dialogue on how to primarily use it “after legitimately exhausting all available options, such as total artificial heart support.”

It might also teach the field to take greater advantage of the many donated hearts discarded as suboptimal. “The general usage rate for offered organs is around a third,” despite opportunities to expand use of those that are “less than perfect,” Dr. Mehra said. “I think that the field will grow with the community focusing on reduced discards of current available heart organs, and not necessarily grow because of the availability of ‘xeno-organs.’ ”

“This field needs to evolve because we’re actively transplanting patients today. But in my mind, the real future is to have such a sufficient understanding of the biology of left ventricular dysfunction that transplantation is a rare event,” Dr. Yancy proposed.

“I’m not certain that heart transplantation per se is the endgame. I think the avoidance of transplantation is the real endgame,” he said. “This may be controversial, but my vision of the future is not one where we have a supply of animals that we can use for transplantation. My vision of the future is that heart transplantation becomes obsolete.”

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

DOACs linked to lower mortality than vitamin K antagonist: 3-year TAVR registry
MDedge Hematology and Oncology
Five risk factors may predict thrombus on LAA occlusion implants
MDedge Hematology and Oncology
STOP-DAPT 2 ACS: 1 month of DAPT proves inadequate for patients with recent ACS
MDedge Hematology and Oncology
Transfusions, readmissions higher for patients with CLL after cardiac surgery
MDedge Hematology and Oncology
Cardiogenic shock teams again tied to lower mortality
MDedge Hematology and Oncology
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MDedge Hematology and Oncology
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
MDedge Hematology and Oncology
Exercise reduces arm and shoulder problems after breast cancer surgery
MDedge Hematology and Oncology
ACC, AHA issue new coronary revascularization guideline
MDedge Hematology and Oncology
Who benefits most from device PFO closure after a stroke?
MDedge Hematology and Oncology